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A B S T R AC T
Background: Tibetans lose less aerobic exercise capacity in hypoxia compared to lowland Han. We 
tested if inhalation of iloprost (to counter hypoxic pulmonary vasoconstriction) and furosemide 
(to decrease afferent vagal traffic from pulmonary receptors) improve performance in hypoxia in 
Han compared to Tibetans. Methods: 8 Tibetans and 8 Han, living at 2,260 m, did incremental uphill 
treadmill running to exhaustion at ambient pressure on day 1, followed by three runs at 5,000 m 
(hypobaric chamber) after inhalation of iloprost (ILO), furosemide (FUR) or placebo (PLA), on different 
days in a counter-balanced order. Results: In Han the performance decrement from 2,260 m to 5,000 
m was greater than in Tibetans (p<0.05). In Han iloprost improved performance at 5,000 m compared 
to placebo (p<0.05 vs. PLA); furosemide had no effects. In Tibetans there were no treatment effects. 
Peripheral O2 saturations at peak exercise at 5,000 m, were higher by ~8 % in the Tibetans (p<0.05 
vs. Han). Maximum heart rate was lowered by 13±6 bpm in Han at 5,000 m regardless of treatment 
compared to 2,260 m (p<0.05). Tibetans reached similar maximum heart rates ~200 bpm at 5,000 
m and 2,260 m, independent of treatment. Conclusions: The blunting of the exercise impairment 
in severe hypoxia in Han during maximal exercise after inhalation of iloprost suggests that hypoxic 
pulmonary vasoconstriction and right ventricular function are potential performance limiting factors 
in Han in hypoxia.
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Introduction
Exercise-induced arterial hypoxemia  impairs maximum 
aerobic capacity (Dempsey & Wagner, 1999; Nielsen, 2003). 
This effect is exacerbated at high altitude because of lower 
inspiratory oxygen tension (PiO2) (Amann & Calbet, 2008). Up 
to altitudes ~4,000 m the loss of aerobic capacity in hypoxia 
is determined by a decrease in arterial oxygen saturation 
(SaO2) and thus arterial oxygen concentration (CaO2) and mass 
arterial oxygen flux (CaO2 x cardiac output = QaO2) (Amann 
& Calbet, 2008; Chapman, Emery, & Stager, 1999; Chapman, 
Stager, Tanner, Stray-Gundersen, & Levine, 2011; Ferretti, Moia, 
Thomet, & Kayser, 1997). However, during exercise in more 
severe hypoxia (above ~4,000 m), when SaO2 drops below 80 
% (Wagner, 2000), there are unexplained reductions in both 
maximum heart rate and cardiac output (Amann & Kayser, 2009; 
Boushel et al., 2001; Kayser, Narici, Binzoni, Grassi, & Cerretelli, 
1994; Mourot, 2018). The impaired maximal cardiac function 
at peak exercise in hypoxia is restored rapidly by increasing 
PiO2 to normoxic levels, enabling heart rate and cardiac output 
to further increase with increasing exercise intensity. The 
underlying mechanisms of the impaired maximum heart rate 
and associated reduction in cardiac output in severe hypoxia 
remain uncertain. 
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A possible explanation for the drop in cardiac output in hypoxia 
is the development of hypoxic pulmonary vasoconstriction 
(HPV) (Naeije & Chesler, 2012; Naeije et al., 2010) . Whilst 
controversy remains, HPV-induced pulmonary hypertension 
would lead to right ventricular over-load, limiting cardiac 
output and impairing maximum aerobic capacity (Anholm 
& Foster, 2011; Naeije, 2011). Among Han lowlanders acutely 
exposed to an altitude of 3,700 m, 61% developed borderline or 
confirmed HPV and had impaired right ventricular function at 
high altitude. This compromised their cardiorespiratory fitness 
in relation to their mean pulmonary arterial pressure (PAP) (Yang 
et al., 2014). Tibetans, a well-adapted high altitude population 
(Wu & Kayser, 2006), have a blunted HPV (Groves et al., 1993) , 
maintain higher arterial oxygen saturation (Marconi et al., 2004; 
Wu & Kayser, 2006), reach higher peak heart rates and show less 
performance decrement during hypoxic exercise compared to 
Han lowlanders (Marconi et al., 2004; Niu, Wu, Li, Chen, & Song, 
1995; Sun et al., 1990; Wu & Kayser, 2006; Zhou, Zhuang, Wu, 
Zhang, & Cherdrungsi, 2008; Zhuang et al., 1993). If the greater 
loss of aerobic performance in hypoxia of Han compared 
to Tibetans is due to more HPV, the inhalation of iloprost, a 
prostacyclin analogue which decreases pulmonary vascular 
resistance (Olschewski et al., 2002; Waxman & Zamanian, 2013) 
and improves endurance exercise performance in primary 
pulmonary hypertension patients (Wensel, Opitz, Ewert, Bruch, 
& Kleber, 2000) could potentially improve endurance exercise 
performance in hypoxia in Han as compared to Tibetans.
Another possible explanation for the observed decrease in 
lower peak heart  and cardiac output in lowlanders exercising in 
severe hypoxia is increased parasympathetic activity (Boushel 
et al., 2001). A potential origin for increased parasympathetic 
activity is activation of pulmonary vagal afferents caused by 
subclinical interstitial pulmonary oedema from hypoxia and 
exercise-induced increased PAP (Anholm, Milne, Stark, Bourne, 
& Friedman, 1999; Bhagat et al., 2011; Cremona et al., 2002; 
Lee & Pisarri, 2001; Paton, 1998). Inhaled furosemide alleviates 
dyspnoea and improves endurance exercise performance 
under certain pathological conditions, possibly through 
pulmonary vagal afferent inhibition (Jensen, Amjadi, Harris-
McAllister, Webb, & O’Donnell, 2008; Newton, Davidson, 
Macdonald, Ollerton, & Krum, 2008; Parshall et al., 2012). We 
hypothesized that inhalation of furosemide by preventing 
activation of pulmonary vagal receptors would increase peak 
heart rate and improve endurance exercise performance in 
hypoxia in Han but not in Tibetans.
We therefore assessed endurance exercise performance in 
Tibetans and Han living at 2,260 m during incremental uphill 
treadmill running, first at ambient pressure and then in a 
hypobaric chamber at a simulated altitude of 5,000 m. We 
compared the effect of inhaled iloprost , furosemide and placebo 
on running performance at 5,000 m expecting that iloprost and 
furosemide would improve performance during incremental 
treadmill running in severe hypoxia in Han but not in Tibetans.
Methods
Participants
Two groups of eight healthy non-smoking Han and Tibetan 
men volunteered to participate (Table 1). The Han were born 
and raised in Xining (2,260 m) and had lived there for most of 
their lives. The Tibetans (and their parents) were born at altitude 
(3,778±196 m, mean±SD) and were studying in Xining (2,260 
m) since 1-3 yr, spending their summer and winter holidays at 
home (3,750 to 4,280 m). They were recruited by word of mouth 
from the local student population.
All participants were seen by a physician for a medical history 
and a physical examination. Inclusion criteria were age 18-25 
years, parents and grandparents of exclusively Tibetan or Han 
ethnicity, respectively, and no contra-indications for exercise 
stress testing. The protocol was approved by the Qinghai High 
Table 1: Participant characteristics.
Tibetan Han
N 8 8
Age (yr) 20±2 20±1
Height (cm) 171±5 179±4*
Body mass (kg) 59±8 77±18*
Time spent at altitude (yr) 19±2 19±1
ABP (sys/dia, mmHg) 116±10 / 72±6 128±11 / 77±10
SaO2 (%) 94±1 94±2
Hb (g/L) 158±9 164±91
Ht (%) 47±2 49±2
*p<0.05; 1p=0.09; ABP: arterial blood pressure; SaO2: pulse oximetry; Hb: haemoglobin; Ht: haematocrit
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Altitude Medical Science Institutional Committee on Human 
Research. Written informed consent was obtained from all 
participants, in accordance with the Declaration of Helsinki.
Resting measurements
At ambient pressure, after 5-10 min rest sitting, blood pressure 
was measured by auscultation using a sphygmomanometer, 
and heart rate and saturation (SaO2) with a finger oximeter 
(Nonin, Plymouth, MN, USA) in triplicate with 2 min intervals 
and averaged. A supine resting ECG was then recorded. A 
venous blood sample was taken from a cubital vein for the 
determination of haemoglobin concentration ([Hb]) and 
haematocrit (Hct) (Sysmex 2000i, Siemens, Munich, Germany). 
Exercise test
The participants performed incremental exercise tests on a 
treadmill (h/p/Cosmos, Rome, Italy), first walking and then 
running, according to a modified Bruce protocol (3 min stages 
at the following speeds and slopes: 2.7 km/h at 0 % (warm-
up), 2.7 km/h at 10 % (stage 1), 4.0 km/h at 12 % (stage 2), 5.4 
km/h at 14 % (stage 3), 6.8 km/h at 16 % (stage 4), 8.0 km/h 
at 18 % (stage 5), until voluntary exhaustion under strong 
verbal encouragement. We chose running over cycling in order 
to allow the participants to engage in a type of large muscle 
group effort they were well-accustomed to. Ear pulse oximetry 
and 12 lead pre-cordial ECG were continuously monitored 
(Masterscreen, Carefusion, Höchberg, Germany). 
Simulated altitude measurements
The exercise testing at a simulated altitude of 5,000 m 
was done in a hypobaric chamber with no blinding to the 
condition (High Altitude Medical Research Institute, Xining, 
Qinghai, China). The pressure was gradually lowered over 
40 min to reach the final altitude. Fractions of oxygen and 
carbon-dioxide were monitored by the chamber’s control 
system and kept at their normal ambient values. Total exposure 
time lasted 3 to 4 hr per session. The intervention consisted 
of iloprost (5 µg in saline, Roche, Switzerland), furosemide (40 
mg in saline, Mepha, Basel, Switzerland) or placebo (saline 
only), inhaled over 10-15 min with an ultrasound nebulizer 
(AeronebGO, Galway, Ireland) each on a different day. After 
decompression the participants inhaled the intervention 
substance, according to a between-group counter-balanced 
randomization scheme to prevent bias from repeated simulated 
altitude exposure. The sequence list for the participants was 
identical in the two groups: 1-3-2, 2-1-3, 3-2-1, 1-3-2, 2-1-3, 
3-2-1, 1-3-2, 2-1-3, where 1 was placebo, 2 furosemide and 3 
iloprost. Participants and experimenters were blinded to the 
substances. The participants then mounted the treadmill. 
After a standing resting measurement they started exercising 
until they reached voluntary exhaustion under strong verbal 
encouragement. At the completion of the exercise test the 
participant was gradually decompressed to the ambient 
atmospheric pressure over 30 min.
Analysis and statistics
Resting measurements at ambient pressure and at 5,000 m 
in the chamber were compared with t-tests. We analysed the 
effects of ethnicity and treatment (i.e. placebo, furosemide 
or iloprost) during exercise using a two-way (ethnicity and 
treatment) ANOVA. Pairwise comparisons (Tukey HSD) were 
then performed between means.  Data are presented as mean 
± SD or 95% confidence interval (CI). An α-level of 0.05 was 
used to interpret our findings. Analysis was done with SPSS (22, 
IBM, NY, USA) and Prism (6.0f, Graphpad, La Jolla, CA, USA).
Results
Resting variables at ambient pressure (2,260 m)
Participant characteristics and resting values are shown in 
Table 1. Han and Tibetans were similar with the exception of 
the slightly higher stature and body mass of the Han.
Simulated altitude of 5,000 m
Exposure to 5,000 m was well tolerated; none of the participants 
reported signs of acute mountain sickness. There were no 
side effects reported of the inhalation of placebo, iloprost or 
furosemide. Resting ECG was normal in all conditions, with sinus 
tachycardia during exposure to 5,000 m. Two out of eight Han 
and two out of eight Tibetans had slight right axis deviations. 
On average acute exposure to 5,000 m lowered total (placebo) 
exercise time by 127±64 sec (P<0.001 vs. 2,260 m).
Figure 1: Time to exhaustion during incremental uphill run-
ning. Dots indicate individuals. Bars and flankers 
indicate means±SD.
Regardless of the altitude, exercise time was consistently better 
in Tibetans (P=0.020 vs. Han). Compared to 2,260 m, exercise 
time at 5,000 m was shortened by 10% for Tibetans (P<0.001) 
and by 18% for Han (P<0.001), the Tibetans exercising 
significantly longer than the Han (P=0.006). Compared to 
placebo, furosemide inhalation did not change exercise time 
in Tibetans (P=0.399) or Han (P=0.823). Meanwhile, iloprost 
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Tibetans, exercise at 5,000 m lowered maximum heart rate by 
5±3 bpm (P=0.027) with placebo. Meanwhile, no difference in 
maximum heart rate was observed with furosemide and iloprost 
compared to placebo in Tibetans during exercise at 5,000 m.
Discussion
This study examined the effects of inhalation of iloprost 
and furosemide on incremental inclined treadmill running 
performance at 5,000 m in Han and Tibetans. We report three 
unique findings: 1) Inhalation of iloprost improved running 
performance by ~50 sec (95% CI, 15 to 86 sec) in Han Chinese 
at 5,000 m, while it had no effect in the Tibetans (95% CI, -35 to 
36 sec); 2) Inhalation of furosemide had no significant effects in 
either Han or Tibetans; and 3) During maximal exercise at 5,000 
m, the Tibetans were able to reach very high maximum heart 
rates (~200 bpm), not yet reported before at such altitude, 
while maintaining a significantly better arterial saturation as 
compared to the Han.
Iloprost
Prostacyclin is a potent pulmonary vasodilator synthesized 
in the endothelium. It targets the IP receptor in the smooth 
muscle cells of the pulmonary vasculature. IP recepter 
activation triggers conversion of ATP to cyclic-AMP, which 
increases protein-kinase-A activity, leading to downstream 
effects including vasodilation (Humbert & Ghofrani, 2015). 
Iloprost is a prostacyclin analogue. When inhaled its pulmonary 
vasodilatory potency is similar to that of prostacyclin, but the 
effects last longer (30 to 90 min, vs. 15 min for prostacyclin 
(Olschewski et al., 2002; Waxman & Zamanian, 2013)). In our 
iloprost-naïve participants we used the recommended initial 
dose of 10 microgram, which was inhaled over a period of 
about 10-15 min prior to the start of the resting measurements. 
The full testing sequence was completed within an hour, so 
that our results were obtained inside the therapeutic window 
of inhaled iloprost. We found that iloprost inhalation improved 
performance in Han at 5,000 m, while no effect was observed 
in the Tibetans (Table 3). Wensel et al.(2000) reported that 
iloprost inhalation decreased pulmonary vascular resistance 
and improved exercise time by 16% in primary pulmonary 
hypertension patients. Therefore, whilst speculative, we 
attribute the improvement in running performance we 
found in the Han to an attenuation of hypoxia-induced 
pulmonary hypertension during maximum exercise with 
iloprost. However, since we were unable to measure PAP 
during exercise, strong conclusions cannot be drawn. Our 
findings would seem to support recent observations of a 
relationship between borderline pulmonary hypertension 
and aerobic exercise performance in young otherwise healthy 
Chinese lowlanders in conditions of acute and chronic altitude 
exposure (Yang et al., 2014). Our data also corroborate reports 
of partial improvements (10–25 %) in maximal exercise 
inhalation improved exercise time in Han (P=0.008) but not 
in Tibetans (P=0.419). As a result, no significant difference in 
exercise time was observed anymore between the Han and 
Tibetan upon iloprost inhalation.
Saturation
Ascent to 5,000 m lowered SaO2 in both Tibetans and Han 
(P<0.001), an effect exacerbated with exercise (P=0.001). A 
smaller reduction in SaO2 was observed in the Tibetans during 
exercise compared to Han (interaction: P=0.040). As a result 
SaO2 during exercise was consistently higher in Tibetans 
compared to Han (P=0.008). Accordingly, CaO2 during exercise 
was lowered at 5,000 m (P<0.001), with lesser reduction 
observed in the Tibetans compared to Han (interaction: 
P=0.013). Regardless of the ethnicity, there were no effects 
of inhaled furosemide or iloprost on SaO2 at exhaustion, i.e. 
exhaustion was reached at similar SaO2.
Figure 2: Saturation at maximum exercise effort. Dots indicate 
individuals. Bars and flankers indicate means±SD.
Maximum heart rate
No difference in maximum heart rate was observed between 
Tibetan and Han during exercise at 2,260 m (P=0.361). During 
exercise at 5,000 m, for any given submaximal exercise 
intensity, HR was higher compared to at 2,260 m (P=0.035). The 
absolute increase in HR during exercise was greater in Tibetans 
(interaction: P=0.009), due to the higher maximal exercise 
intensity achieved compared to Han. In Han, maximum heart 
rate was decreased by 13±6 bpm during exercise at 5,000 m 
with placebo (P<0.001). Compared to placebo, neither iloprost 
nor furosemide influenced maximum heart rate in the Han. In 
Figure 3: Heart rate at maximum exercise effort. Dots indicate 
individuals. Bars and flankers indicate means±SD.
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capacity in hypoxia with other specific pulmonary vasodilating 
interventions (Ghofrani et al., 2004; Naeije & Dedobbeleer, 
2013). Since iloprost had no effect in the Tibetans, our results 
would then suggest that HPV is not a limiting factor for exercise 
performance in the Tibetan population. Nevertheless, our data 
provide only limited evidence supporting a role for HPV in 
limiting performance in Han at high altitude.
Furosemide
Others proposed that the decrease in maximum heart rate at 
altitude is due to increased parasympathetic activity (Bao et 
al., 2002; Boushel et al., 2001).  Furosemide is a loop diuretic 
which inhaled can alleviate symptoms of dyspnea (Newton 
et al., 2008; Parshall et al., 2012), perhaps through pulmonary 
vagal receptor inhibition, decreasing vagal afferent traffic (Lee 
& Pisarri, 2001; Newton et al., 2008).  We therefore hypothesized 
that heart rate during maximal exercise in hypoxia would 
increase under inhalation of furosemide because of less 
parasympathetic activity. In the present study, maximum heart 
rate was not significantly different in the Han after furosemide 
inhalation compared to placebo (+2 bpm [95% CI,  -2 to +6]). 
Accordingly, this finding refutes our hypothesis of pulmonary 
receptor stimulation causing increased parasympathetic 
activity limiting maximum heart rate during hypoxic exercise. 
However, pulmonary receptors and their role in limiting 
maximum heart rate in severe hypoxia are still not yet well 
understood (Widdicombe, 2009).  In rabbits basal rapid adapting 
pulmonary receptor (RAR) activity increases during prolonged 
exposure to hypoxia accompanied by pulmonary congestion 
(Bhagat et al., 2011). In humans, exposure to high altitude 
is accompanied by pulmonary congestion and subclinical 
interstitial pulmonary edema (Anholm et al., 1999; Cremona 
et al., 2002). It therefore remains possible that increased PAP 
(from altitude and exercise) and interstitial oedema would 
stimulate vagal pulmonary receptors, leading to increased 
parasympathetic activity, in turn leading to decreased peak 
heart rates, even though the absence of an effect of inhaled 
furosemide in our study would argue against this contention.
Maximum heart rates in Tibetans
Strikingly, on average our Tibetan participants reached peak 
heart rates above 200 bpm, independently of the altitude or the 
intervention, contrary to what was expected from the extant 
literature (Mourot, 2018). Our participants were young (20±2 
yr) and heart rates around 200 bpm were therefore expected 
in normoxic conditions, but not necessarily at 2,260 m, and 
certainly not at 5,000 m. More important, the Tibetans reached 
similar peak heart rates in all conditions. This finding is contrary 
to the prevailing view of decreased peak heart rates above 
about 4,000 m (Bao et al., 2002; Boushel et al., 2001; Wagner, 
2000). At lower altitudes peak heart rate remains similar to 
that observed at sea level, but beyond 4,000 m peak heart rate 
progressively decreases with increasing altitude, while chronic 
exposure to hypoxia decreases it even further, because of the 
increased CaO2 from the increased haemoglobin. For example, 
Danish climbers attempting Mt Everest, who prior to departure 
had mean peak heart rates of 186 bpm in normoxia, and 170 
bpm in acute hypoxia (10 % O2 in N2), after acclimatization at 
5,400 m reached peak heart rates of only 155 bpm (Lundby & 
van Hall, 2001). In that study, in two climbers heart rate was 
monitored during ascent to 8,750 m (without supplementary 
O2), with peak rates of only 144 and 148 bpm, respectively.
The reasons for the decrease in peak heart rate in acute and 
chronic severe hypoxia are unknown (Mourot, 2018). In 
lowlanders, after 9 weeks at 5,260 m, vagal blockade with 
glycopyrrolate restored maximum heart rate to sea level values, 
but had no influence on cardiac output or performance, which 
remained reduced, while acutely normalizing FiO2 at peak 
exercise restored cardiac output and power output to sea level 
values (Boushel et al., 2001). Those authors concluded that 
enhanced parasympathetic neural activity accounts for the 
lowering of heart rate during exercise at altitude, but could 
not explain why blocking parasympathetic activity did not 
improve performance. Bao et al. (2002) investigated the effects 
of beta-blockade with propranolol and para-sympathetic 
blockade with glycopyrrolate and reported that increased 
parasympathetic neurotransmitter release and decreased beta-
adrenoreceptor activity account for the decreased peak heart 
rates, despite enhanced sympathetic activity. An acute increase 
in FiO2 rapidly counteracted the parasympathetic, but not the 
sympathetic hyperactivity that occurred at high altitude (Bao 
et al., 2002). Favret and Richalet hypothesized that the drop 
in maximum heart rate in severe hypoxia would prevent 
mismatching between myocardial O2 demand and supply 
(Favret & Richalet, 2007). They reasoned that compensation of 
decreased CaO2 in severe hypoxia by increasing coronary blood 
flow would not be possible anymore above a certain altitude. 
Only by capping maximal heart rate, which would decrease 
myocardial O2 demand, would cardiac integrity be protected. 
Our results suggest that this would not be the case for Tibetans 
exercising maximally at 5,000 m, but leaves the hypothesis to 
be tested in even more severe hypoxia such as found close to 
the summit of Mt Everest (8848 m).
Limiting factors of exercise performance in hypoxia
The impairment of aerobic power and exercise performance in 
severe hypoxia (SaO2<80 %) is still not well understood. Lack of 
oxygen is obviously the reason, but the underlying mechanisms 
that lead to an earlier disengagement from an exercise 
challenge in hypoxia compared to normoxia remain unknown 
(Fan & Kayser, 2016). According to Verges et al. (2012) active 
locomotor muscle metabolic fatigue cannot be the main cause 
of the impaired whole body exercise performance in severe 
hypoxia. Upon reaching exhaustion in hypoxia, participants 
can continue cycling when surreptitiously switched to 
normoxia (Amann et al., 2006; Boushel et al., 2001; Kayser et al., 
1994; Koglin & Kayser, 2013), which also argues in favour of a 
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Limitations
Several important methodological limitations should be 
considered when interpreting our findings. First, iloprost was 
expected to alleviate HPV and thus lower PAP, but we were 
not able to measure PAP. Our results, even though compatible 
with a role for HPV in limiting performance in the Han, should 
therefore be completed with new data including measurements 
of PAP during exercise, e.g. with echo-doppler. Second, since 
we did not measure stroke volume or cardiac output, we could 
only infer cardiovascular changes from observing changes in 
heart rates. However, since there was a clear difference between 
the Han and the Tibetans with regard to heart rate it seems 
likely that they did differ for cardiac output, but this remains 
to be tested, e.g. with acetylene rebreathing, echo-doppler or 
transthoracic impedancemetry. Third, we were unable to recruit 
participants of similar stature, resulting in slightly smaller and 
lighter Tibetan participants compared to their Han Chinese 
counterparts. Our results should therefore be completed with 
measurements in more participants and with similar build. 
Fourth, because of calibration problems of our gas exchange 
apparatus upon decompression to 5,000 m we could not 
obtain reliable gas exchange data. Fifth, we cannot present any 
rates of perceived exertion for leg and breathing effort since 
the participants did not understand the instructions. Sixth, we 
cannot ascertain maximality of the running effort with usual 
criteria such as high RPE, a plateau in VO2, and an RER > 1.1. 
And finally, since we used the actual living altitude of 2,260m 
of our participants as our control condition, and not (acute) 
sea level conditions, we cannot exclude some effect of partial 
acclimatization to high altitude.
Conclusions
We report conserved maximum heart rate and less desaturation 
during maximum exercise in acute severe hypoxia (5,000 
m) in Tibetans compared to Han, allowing the Tibetans to 
outperform the Han. Since inhalation of iloprost blunted the 
exercise impairment in Han during maximal exercise in severe 
hypoxia but had no effect in Tibetans, HPV possibly plays a role 
in the greater impact of hypoxia on maximum exercise capacity 
in Han as compared to Tibetans.
Acknowledgements
We thank the participants for their participation, the technical 
support personnel of the hypobaric chamber at the National 
Key Laboratory of High Altitude Medicine in Xining for their 
expert help, and Aeroneb, Galway, Ireland, for donation of 
nebulizers.
supra-spinal limitation of exercise performance (Fan & Kayser, 
2016). Amann et al. (2007) reported that the degree of hypoxia 
influences the relative role of muscle fatigue in the cessation 
of dynamic exercise with large muscle groups. Those authors 
proposed a threshold of SaO2 for a ‘switch’ from a predominant 
effect of peripheral fatigue to one of a supra-spinal limitation. 
They found similar levels of muscle fatigue at task failure from 
constant load exercise to exhaustion in different conditions of 
inspiratory oxygen tension, when SaO2 averaged 94 %, 82 %, or 
76 % (FiO2 0.21–0.12), but not at a SaO2 of 67 % (FiO2 0.10) when 
apparently supra-spinal limitation led to early disengagement 
of the effort. When reaching exhaustion at 5,000 m our Han 
Chinese participants had on average saturations of about 67 %, 
similar to that of Amann’s participants. This would suggest 
that limitation of exercise at 5,000 m in our Han participants 
may have been less from peripheral muscle fatigue as 
compared to 2,260 m and that supra-spinal effects would 
have played a predominant role. By contrast, our Tibetan 
participants had significantly higher saturations as compared 
to the Han participants, on average remaining higher than 
74 % at maximum exercise, i.e. at or just above the supposed 
‘switch’ value between 76 and 67 % as suggested by Amann 
et al. (2007). It therefore remains possible that the ‘switch’ from 
predominantly peripherally determined fatigue towards a 
supra-spinal mechanism could exist in the Tibetans too, but at 
higher altitudes, when their SaO2 could drop below 67 %. One 
other feature with regard to SaO2 made the Tibetans stand out. 
Apart from being higher, their saturations were all very similar; 
variance was lower as compared to that of the Han, as can be 
clearly seen in Figure 1. We do not have an explanation for 
the better saturations of the Tibetans as compared to the Han 
Chinese, nor for the reduced variance.  An increased affinity 
for oxygen of haemoglobin could play a role. Simonson et al. 
(2014) reported lower haemoglobin P50 in Han Chinese and 
Tibetans at 4,200 m in comparison with low altitude data, but 
no difference between the two groups, excluding a role for P50.
Tibetans and altitude
It is beyond the scope of this study to comprehensively review 
what is known about the Tibetans’ better adaptation to altitude 
as compared to other ethnic groups. But with regard to exercise 
performance there is sufficient research suggesting that 
Tibetans do indeed fare better [see e.g. (Wu & Kayser, 2006)]. 
Tibetans do not have very high aerobic capacity, but are able 
to reach a higher fraction of their low-altitude aerobic capacity 
in hypoxia as compared to lowlanders (Marconi et al., 2004; Niu 
et al., 1995) . Since this characteristic is also present in Tibetans 
born at low altitude this suggests a trait for better altitude 
adaptation (Marconi et al., 2004). Recent work suggests that 
hypoxic exposure over many generations indeed led to the 
selection of specific alleles in Himalayan (Simonson, McClain, 
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